Strategies To Increase Rare Disease Clinical Trial Enrollment

About 400 million people worldwide suffer from a rare disease, but 95% of such conditions do not have an FDA-approved treatment.¹ To make matters worse, more than 25% of rare disease clinical trials are canceled because of a lack of enrollment.¹ Clinical trial retention is also an issue in the rare disease sector.

Here are three strategies to help increase enrollment in rare disease trials to better serve these patients.